In 2009 Mikhail Blagosklonny, who hails from Russia, became part of the Roswell Park Cancer Institute as a professor of oncology with a focus on TOR research to develop a solution to solve the puzzle of cancer.
Research into TOR, which stands for ‘Target of Rapamycin’ and is sometimes called the ‘Engine-of-aging Enzyme,’ is being studied by many others as well. View Mikhail’s profile in LinkedIn
In basic terms; the idea is that a lot of serious illnesses including cancer occur with much greater frequency in people as they get older. Therefore, if an anti-aging solution can be found, or at least partially realized, then the incidences of cancer and other diseases could be dramatically reduced.
There is also the fact that another facet of the overall goal of this approach is that the preventive and treatment procedures will be less painful, time consuming and less expensive.
Mikhail Blagosklonny, who once worked as a senior scientist for the Ordway Research Institute, is not some radical maverick spouting useless rhetoric. His has a highly trained and organized mind and is very devoted to scientific method as shown in this article here on the U.S Government Website: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3615154/
Being rather prolific despite his busy schedule; Mikhail Blagosklonny is also the author of over 300 articles in various publications. He is a sought after editor currently serving as the Associate Editor of Cancer Biology and Therapy, International Journal for Cancer, and the American Journal of Pathology. He is the Founder, Editor and Editor in Chief of Cell Cycle and also an associate editor of the prestigious Journal of Cancer Biology & Therapy.
Read more: http://www.aging-us.com/article/100591/text